Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Summary

Primary objective of this study is to allow access and evaluate the safety of crizotinib for patients in Japan with advanced NSCLC harboring a translocation or inversion involving the ROS1 oncogene.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications